By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quanterix said today it has entered an agreement with Novartis to evaluate its Single Molecule Array, or SiMoA, platform for diagnostic use.

The platform will be evaluated at Quanterix, based in Cambridge, Mass., and will focus on an undisclosed neuron-specific protein target. Financial and other terms of the deal were also undisclosed.

The SiMoA platform is used for the development and commercialization of blood tests that measure protein levels in blood.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.